Thermo Fisher Scientific Announces $11.5Bn Buyout Of Qiagen

 
• By Catherine Longworth and Reed Miller

Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.

M&A, Mergers and Acquisitions. US Dollar texture. - Illustration

More from Deals

More from Business